Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.

Blood advances - 25 Jul 2023

Tatarczuch Maciej, Waltham Mark, Shortt Jake, Polekhina Galina, Hawkes Eliza A, Ho Shir-Jing, Trotman Judith, Brasacchio Daniella, Co Melannie, Li Jessica, Ramakrishnan Vanitha, Dunne Karin, Opat Stephen S, Gregory Gareth P

Abstract excerpt

Using tissue whole exome sequencing (WES) and circulating tumor cell-free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma, B-Cell, Marginal Zone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma Diagnosis and Treatment

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to NF-kappa B

Share to Protein Kinase Inhibitors

Share to Viral-associated cancers and disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 36947202
DOI: 10.1182/bloodadvances.2022009412
PMCID: PMC10368859

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.PMID 36947202Read ↗

Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.Semantic proximity Read ↗

The genetic landscape of histologically transformed marginal zone lymphomasSemantic proximity Read ↗

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone LymphomaSemantic proximity Read ↗

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaSemantic proximity Read ↗

Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.Semantic proximity Read ↗

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclaxSemantic proximity Read ↗

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemiaSemantic proximity Read ↗

The genetics of nodal marginal zone lymphoma.Semantic proximity Read ↗

The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.Semantic proximity Read ↗

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.